Drug intelligence / Profile preview

dexamethasone + neomycin + polymyxin B

Development stage
Approved
Lead developer
Alcon
Modality
Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, RNA-Targeting Small Molecules → Nucleic Acid-Directed Small Molecules → Small Molecules, Antimicrobial Peptides → Native Peptides → Peptides
Administration
Ophthalmic
01

Overview

This is a fixed-dose combination drug containing three active ingredients: dexamethasone (a synthetic corticosteroid), neomycin (an aminoglycoside antibiotic), and polymyxin B (a polypeptide antibiotic). It is primarily used as an ophthalmic preparation to treat or prevent bacterial eye infections and to reduce associated inflammation. Dexamethasone suppresses the inflammatory response by inhibiting multiple inflammatory cytokines and mediators. Neomycin inhibits bacterial protein synthesis by binding to the 30S ribosomal subunit. Polymyxin B disrupts the integrity of the bacterial cell membrane in susceptible Gram-negative bacteria. The combination provides both anti-inflammatory effects (from dexamethasone) and broad-spectrum antibacterial coverage (from neomycin and polymyxin B). It is indicated for steroid-responsive ocular conditions where there is a risk or presence of bacterial infection[1][2][3][5].

Brand names
MaxitrolPoly-DexOcu-TrolDexacidinDexasporinAK-TrolNeoPolyDex
Other names
dexamethasone-neomycin-polymyxin B ophthalmic ointmentneomycin and polymyxin B sulfates and dexamethasone ophthalmic suspension
02

Targets

GR (Glucocorticoid receptor)Bacterial RibosomeLPS (Lipopolysaccharide)

Beyond the preview

Go deeper on dexamethasone + neomycin + polymyxin B.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Full profile access

Follow clinical development from study design and recruitment through results.

  • Trial phase
  • Status
  • Readouts

Indications & development

Full profile access

Explore development by indication, patient population, and geography.

  • Indications
  • Development status
  • Countries

Licensing & deals

Full profile access

Trace asset ownership, licensing agreements, and commercial partnerships.

  • Partners
  • Deal terms
  • Milestones

Patents & exclusivity

Full profile access

Explore the patent landscape and regulatory exclusivity around an asset.

  • Patents
  • Expiration dates
  • Exclusivity

Competitive landscape

Full profile access

Compare development programs by target, modality, and indication.

  • Competing assets
  • Targets
  • Development stage

Research & analysis

Full profile access

Connect source evidence and development news to your research questions.

  • Publications
  • News
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on dexamethasone + neomycin + polymyxin B.

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call